TG Therapeutics Approaches Its First Test of Whether Last Quarter's Miss Was Noise or Pattern
TG Therapeutics (TGTX) reports second-quarter 2026 earnings on August 3, 2026, with analysts expecting $0.41 per share—a dramatic turnaround from the prior year's $0.17. The central question: can the biotech sustain momentum after a volatile earnings track record that has seen both massive beats and disappointing misses, while navigating a challenging year-over-year comparison against last quarter's extraordinary $2.43 result?
Part 1: Earnings Preview
TG Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, with its lead product BRIUMVI (ublituximab) approved for multiple sclerosis. The company also markets UKONIQ for certain lymphomas, positioning it in the competitive oncology and autoimmune disease markets.
TGTX reports Q2 2026 earnings on August 3, 2026, before market open, with the consensus estimate at $0.41 per share from 4 analysts. The company most recently reported $0.17 per share for Q1 2026, missing the $0.23 estimate by 26%. Year-over-year, the $0.41 estimate represents +141% growth versus the $0.17 reported in Q2 2025, signaling expectations for substantial improvement.
Three key themes define this earnings story:
BRIUMVI Commercial Trajectory: Investors are focused on uptake metrics for the multiple sclerosis franchise, which represents the company's primary growth driver. Market penetration rates, prescription trends, and competitive positioning against established MS therapies will determine whether TG can sustain its commercial momentum and justify current valuations.
Profitability Inflection Point: With consensus estimates projecting positive EPS across upcoming quarters, the market is watching whether TG can demonstrate consistent profitability after years of losses. The path to sustained earnings power—including operating leverage, gross margin expansion, and R&D efficiency—will be critical to the investment thesis.
Volatility Management: Last quarter's extraordinary $2.43 result in Q3 2025 (a 912% beat) created difficult comparisons and raised questions about earnings quality and sustainability. Analysts are looking for normalized results that demonstrate underlying business fundamentals rather than one-time items or accounting adjustments.
Analyst commentary ahead of the release reflects cautious optimism, with 6 of 9 analysts maintaining Strong Buy ratings despite recent earnings misses. The wide estimate range ($0.22 to $0.61) suggests significant uncertainty about near-term results, though the longer-term outlook remains constructive with 2027 estimates projecting $2.94 per share—more than double 2026's expected $1.46.
Part 2: Historical Earnings Performance
TG Therapeutics has delivered an inconsistent earnings track record over the past four quarters, with a pattern of significant misses punctuated by one extraordinary beat. The company missed estimates in three of the last four quarters, with shortfalls of -46.87% (Q2 2025), -60.00% (Q4 2025), and -26.09% (Q1 2026). The lone exception was Q3 2025's stunning +912.50% beat, when the company reported $2.43 versus a $0.24 estimate—a result that appears anomalous given the surrounding pattern of underperformance.
The magnitude of the misses has been substantial, with the company falling short by an average of 44% in the three disappointing quarters. This pattern suggests either overly optimistic analyst expectations, execution challenges in the commercial ramp, or timing issues with revenue recognition and expenses. The Q3 2025 outlier—which delivered ten times the expected earnings—raises questions about whether that result reflected one-time gains, milestone payments, or accounting adjustments rather than sustainable operating performance.
Heading into Q2 2026, investors face uncertainty about which pattern will prevail: the disappointing misses that characterized most recent quarters, or results closer to normalized profitability expectations. The company's inability to consistently meet estimates creates risk for the upcoming release, particularly given the elevated $0.41 consensus—more than double the $0.17 reported in both Q2 2025 and Q1 2026.
| Quarter | EPS Estimate | EPS Actual | Surprise % | Beat/Miss |
|---|---|---|---|---|
| Jun 2025 | $0.32 | $0.17 | -46.87% | Miss |
| Sep 2025 | $0.24 | $2.43 | +912.50% | Beat |
| Dec 2025 | $0.35 | $0.14 | -60.00% | Miss |
| Mar 2026 | $0.23 | $0.17 | -26.09% | Miss |
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
TG Therapeutics reports before market open, meaning Day 0 captures the first full trading session reaction while Day +1 reflects follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-06 | +$5.87 (+16.26%) | $5.84 (16.18%) | +$1.05 (+2.51%) | $2.84 (6.77%) |
| 2026-02-26 | +$1.24 (+4.18%) | $3.31 (11.17%) | -$0.81 (-2.62%) | $1.23 (3.96%) |
| 2025-11-03 | -$1.09 (-3.13%) | $5.43 (15.61%) | +$0.12 (+0.36%) | $1.56 (4.63%) |
| 2025-08-04 | -$6.30 (-17.99%) | $3.92 (11.19%) | -$0.32 (-1.11%) | $1.77 (6.16%) |
| 2025-05-05 | -$5.76 (-13.26%) | $4.86 (11.19%) | -$2.82 (-7.48%) | $3.24 (8.60%) |
| 2025-03-03 | +$4.33 (+14.39%) | $6.12 (20.34%) | +$1.20 (+3.49%) | $2.79 (8.11%) |
| 2024-11-04 | -$2.54 (-9.44%) | $2.13 (7.92%) | +$1.50 (+6.16%) | $2.42 (9.93%) |
| 2024-08-06 | +$3.37 (+19.58%) | $2.88 (16.73%) | -$0.59 (-2.87%) | $2.18 (10.59%) |
| Avg Abs Move | 12.28% | 13.79% | 3.33% | 7.34% |
Historical price action around earnings shows significant volatility, with an average absolute Day 0 move of 12.28% and Day 0 range of 13.79%. The most recent release on May 6, 2026, triggered a +16.26% surge despite the earnings miss, suggesting the market focused on other positive factors such as revenue beats or forward guidance. However, the pattern has been inconsistent—prior releases in August 2025 and May 2025 both saw sharp declines of -17.99% and -13.26% respectively on Day 0.
The Day +1 follow-through has been more muted, averaging 3.33% with a 7.34% range, indicating most of the price discovery occurs in the immediate reaction session. Investors should prepare for a potential double-digit percentage move in either direction based on not just the headline EPS result, but also revenue performance, guidance updates, and commentary on the commercial trajectory. The wide historical range suggests options strategies may be appropriate for those seeking to manage risk around the announcement.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 21) |
| Expected Move | $6.04 (11.64%) |
| Expected Range | $45.83 to $57.90 |
| Implied Volatility | 70.91% |
The options market is pricing an 11.64% expected move for the August 21 expiration, slightly below the 12.28% average historical Day 0 move but well within the typical range. This suggests options traders are anticipating meaningful volatility but not an outsized reaction compared to recent history, despite the elevated earnings estimate and uncertain track record.
Part 3: What Analysts Are Saying
Analysts maintain a bullish stance on TG Therapeutics with an average recommendation of 4.22 out of 5.00, reflecting a Strong Buy consensus. The breakdown shows 6 Strong Buy ratings, 2 Hold ratings, and 1 Moderate Sell, with no Strong Sell recommendations among the 9 analysts covering the stock. This represents unchanged sentiment from one month ago, indicating stable conviction despite recent earnings volatility.
The average price target of $63.50 implies 22.1% upside from the current price of $52.03, with a wide range spanning from a low target of $20.00 to a high of $86.00. The $66.00 spread between high and low targets reflects divergent views on the company's commercial execution and path to sustained profitability. The most bullish analysts see potential for 65% upside if BRIUMVI adoption accelerates and the company demonstrates operating leverage, while the bearish outlier at $20.00 suggests concerns about competitive pressures or execution risk.
The maintained Strong Buy consensus despite three earnings misses in the last four quarters indicates analysts are looking past near-term volatility and focusing on the longer-term opportunity. The 2027 estimate of $2.94 per share—more than double the 2026 forecast—suggests the analyst community expects meaningful earnings growth as the commercial infrastructure matures and the company achieves scale.
Part 4: Technical Picture
The Barchart Technical Opinion stands at 80% Buy, down from 100% Buy one week ago and one month ago, indicating some recent deterioration in technical momentum heading into the earnings release. The stock is currently trading at $52.03, positioned below its 5-day ($53.93), 10-day ($54.18), and 20-day ($55.24) moving averages, but above its 50-day ($49.92), 100-day ($42.33), and 200-day ($36.68) moving averages.
Timeframe Analysis:
- Short-term (50% Buy): Moderate buy signal suggests near-term momentum has weakened from recent highs, with the stock pulling back from its 20-day moving average
- Medium-term (100% Buy): Strong buy signal indicates the intermediate trend remains firmly positive, supported by the stock's position well above the 50-day moving average
- Long-term (100% Buy): Strong buy signal reflects robust longer-term uptrend, with the stock trading 42% above its 200-day moving average
Trend Characteristics: The Strong strength combined with Average direction suggests a well-established uptrend that has entered a consolidation phase, creating a neutral-to-slightly-cautious backdrop for the earnings event.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $53.93 | 50-Day MA | $49.92 |
| 10-Day MA | $54.18 | 100-Day MA | $42.33 |
| 20-Day MA | $55.24 | 200-Day MA | $36.68 |
The technical setup presents a mixed picture heading into earnings. While the longer-term trend remains constructive with the stock holding well above its 200-day moving average at $36.68, the recent pullback below short-term moving averages and weakening near-term momentum signal caution. The stock has given back ground from recent highs near $55, creating overhead resistance in the $53-$55 zone. Support appears solid at the 50-day moving average around $50, which has contained recent weakness. Given the 11.64% expected move and historical 12.28% average reaction, a break above $55 on strong results could target the $58-$60 range, while disappointment could test the $47-$50 support zone. The technical deterioration from 100% Buy to 80% Buy over the past month suggests some profit-taking ahead of the event, potentially setting up for a "sell the news" reaction even on in-line results.
